Eli Lilly is spending up to $2.88 billion to acquire Merida Biosciences and expand into autoimmune treatments, signaling a push to diversify beyond its blockbuster obesity drugs and manage future growth risks
Eli Lilly is allocating $2.88 billion to acquire Merida Biosciences, directly addressing its exposure to the unpredictable performance of its obesity drug portfolio. Mounjaro and Zepbound have driven a 47.67% year-over-year revenue increase to $22.97 billion in the latest quarter, elevating Lilly's market capitalization and P/E ratio of 39.32 well above sector averages. However, this concentration leaves the company susceptible to regulatory, pricing, or demand disruptions in the GLP-1 drug category.
On August 31, 2026, Eli Lilly and Merida Biosciences announced a definitive agreement for Lilly to acquire Merida for up to $2.875 billion in cash, including milestone payments, with the deal expected to close in the fourth quarter of 2026 pending regulatory approvals.
Strategic Diversification
Lilly's purchase of Merida follows recent immunology acquisitions, including Ventyx Biosciences for $1.2 billion and Orna Therapeutics for up to $2.4 billion, as reported by BioPharma Dive. This pattern demonstrates a strategy of converting short-term obesity gains into long-term investments in emerging science. Merida's lead candidate, MER511, targets Graves' disease and thyroid eye disease-conditions affecting approximately 1% of Americans-by selectively eliminating pathogenic autoantibodies rather than broadly suppressing the immune system. A second asset, MER769, is in development for food allergies and asthma. According to the official company press release, Merida's approach seeks to minimize infection risk and side effects commonly associated with traditional immunosuppressants.
Deal Structure and Risk Management
The Merida acquisition fits into Lilly's broader M&A strategy for 2026, which has included the purchases of Ventyx Biosciences for approximately $1.2 billion and Orna Therapeutics for up to $2.4 billion, reflecting an aggressive expansion of its immunology pipeline.
Competitive Landscape and Valuation Pressure
Even if Merida's pipeline succeeds, it will compete with established players such as Amgen's Tepezza and Viridian Therapeutics' Lumvoa in the thyroid eye disease market, as noted by CNBC. Lilly is paying a premium for early-stage assets-Merida had raised only $121 million prior to this deal-intensifying the risk of clinical or commercial setbacks. With thirteen acquisitions this year, Lilly's pipeline is broad but also exposed to the high attrition rate typical of early-stage biotech.
Valuation remains a key concern. Lilly's P/E multiple of 39.32 significantly exceeds that of most large pharmaceutical peers, reflecting investor expectations for continued growth. Any disruption in the obesity franchise or a series of unsuccessful pipeline investments could prompt a sharp correction. The Merida acquisition will not contribute to near-term earnings, so investors seeking immediate returns should adjust their expectations accordingly.
Long-Term Outlook
Lilly's shares closed at $1,170.98 on September 2, up 0.95% for the day and 8.39% year-to-date, but still below the 52-week high of $1,292.65. The Merida deal will not impact these figures this quarter, but it does alter the company's risk profile by expanding beyond GLP-1s. For long-term investors, this diversification reduces concentration risk and positions Lilly for future growth in immunology and allergy therapeutics.
Despite this strategic pivot, Lilly's performance remains closely linked to Mounjaro and Zepbound. The Merida acquisition serves as a long-term hedge rather than a short-term catalyst. Investors should calibrate their exposure accordingly, recognizing that even leading market players can experience sharp corrections if expectations are not met. Lilly's management is using its obesity-driven gains to secure a position in next-generation autoimmune therapies-a strategy that could succeed if the underlying science proves out, but one that also exposes shareholders to the volatility inherent in early-stage biotech. The company's assertive acquisition approach distinguishes it from peers, but also increases the risk of overpaying for unproven assets. Ultimately, the Merida deal represents a calculated risk, reflecting both the opportunities and challenges of relying on innovation to drive long-term growth.
Autoimmune diseases remain a significant focus for pharmaceutical innovation, as traditional therapies often suppress the entire immune system and elevate infection risk. Merida's targeted approach-neutralizing only harmful antibodies-offers the potential for safer, more effective treatments, but its efficacy at scale remains unproven. Investors should carefully consider both the scientific and commercial risks before increasing exposure to companies making substantial investments in early-stage breakthroughs.
